Drug Profile
Diphtheria, tetanus and pertussis vaccine infant- Tianjin CanSino Biotechnology
Alternative Names: Component pertussis-based infants vaccine; Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed - Tianjin CanSino Biotechnology; DTcP vaccine (infant)- Tianjin CanSino BiotechnologyLatest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Tianjin CanSino Biotechnology
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Diphtheria; Pertussis; Tetanus
Most Recent Events
- 25 Aug 2023 Phase-III clinical trials in Tetanus (In infants, Prevention) in China (IM) (NCT05951725)
- 11 Aug 2023 Phase-III clinical trials in Diphtheria (In infants, Prevention) in China (IM) (NCT05951725)
- 11 Aug 2023 Phase-III clinical trials in Pertussis (In infants, Prevention) in China (IM) (NCT05951725)